HC Wainwright Issues Positive Estimate for OVID Earnings

Ovid Therapeutics Inc. (NASDAQ:OVID) – Equities researchers at HC Wainwright lifted their Q1 2025 EPS estimates for Ovid Therapeutics in a research note issued to investors on Monday, March 24th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.13) per share for the quarter, up from their prior forecast of ($0.16). HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Ovid Therapeutics’ Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.15) EPS, Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.15) EPS and Q4 2026 earnings at ($0.16) EPS.

Ovid Therapeutics (NASDAQ:OVID) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03. Ovid Therapeutics had a negative return on equity of 39.24% and a negative net margin of 5,142.56%. The business had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.19 million.

Several other analysts have also recently commented on the company. Wedbush restated an “outperform” rating and set a $3.00 target price (down previously from $4.00) on shares of Ovid Therapeutics in a report on Wednesday, March 12th. Oppenheimer raised Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4.00 price target for the company in a research note on Wednesday, January 29th. Finally, BTIG Research dropped their price objective on Ovid Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Monday. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $3.03.

Ovid Therapeutics Price Performance

Shares of Ovid Therapeutics stock opened at $0.41 on Wednesday. The stock has a market capitalization of $28.93 million, a price-to-earnings ratio of -0.87 and a beta of 0.29. Ovid Therapeutics has a 1-year low of $0.40 and a 1-year high of $3.45. The firm’s 50-day moving average price is $0.59 and its two-hundred day moving average price is $0.92. The company has a current ratio of 5.66, a quick ratio of 5.66 and a debt-to-equity ratio of 0.18.

Hedge Funds Weigh In On Ovid Therapeutics

A number of large investors have recently bought and sold shares of OVID. Takeda Pharmaceutical Co. Ltd. bought a new position in Ovid Therapeutics in the fourth quarter valued at approximately $7,012,000. Adage Capital Partners GP L.L.C. bought a new stake in Ovid Therapeutics in the 4th quarter valued at about $934,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Ovid Therapeutics by 50.2% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 943,416 shares of the company’s stock worth $881,000 after buying an additional 315,126 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Ovid Therapeutics in the fourth quarter worth $272,000. Finally, BNP Paribas Financial Markets raised its position in shares of Ovid Therapeutics by 4,128.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 220,401 shares of the company’s stock valued at $260,000 after buying an additional 215,189 shares in the last quarter. Institutional investors and hedge funds own 72.24% of the company’s stock.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.